Adalimumab Expectations Revised In The Wake Of Amgen Launch
Analysts Outline Predictions And Weigh In On Key Questions Yet To Be Answered
The launch of Amgen’s Amjevita, the first US biosimilar rival to Humira, has been accompanied by multiple fresh forecasts of how competition could play out this year, with a host of further biosimilar launches on the horizon.
You may also be interested in...
Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars
Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.
Amgen Talks Dual Pricing Strategy For Amjevita
In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.
The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.